论文部分内容阅读
目的探讨以全身照射(TBI)为主的预处理方案治疗T细胞淋巴瘤患者的疗效。方法回顾性分析行自体造血干细胞移植(AHSCT)的T细胞淋巴瘤患者12例资料。随访TBI+CY预处理方案移植后的造血重建情况、移植并发症和生存情况。结果所有患者移植后造血功能均顺利重建,中性粒细胞数≥0.5×109/L的时间为移植后10-15d,血小板数≥20×109/L的时间为移植后11-16d。随访时间为8-60个月,复发率25%(3/12),病死率16.7%(2/12),2年的无病生存率75%(9/12)。结论以TBI为主治疗T细胞淋巴瘤的预处理方案是安全、有效的。
Objective To investigate the efficacy of systemic intervention (TBI) -based pretreatment in patients with T-cell lymphoma. Methods The clinical data of 12 patients with T-cell lymphoma who underwent autologous hematopoietic stem cell transplantation (AHSCT) were retrospectively analyzed. Follow-up TBI + CY preconditioning regimen after hematopoietic reconstructions, complications and survival of the transplant. Results All patients had successful reconstruction of hematopoietic function after transplantation. The number of neutrophils≥0.5 × 109 / L was 10-15 days after transplantation, and the number of platelets≥20 × 109 / L was 11-16 days after transplantation. The follow-up time ranged from 8 to 60 months. The recurrence rate was 25% (3/12) and the case fatality rate was 16.7% (2/12). The 2-year disease-free survival rate was 75% (9/12). Conclusion TBI-based T-cell lymphoma pretreatment regimen is safe and effective.